Objective To retrospectively analyze the clinical efficacy and adverse effect of FOL-FOX-4 regimen (oxaliplatin combined with fluorouracil and leucovorin) and DF regimen (do-cetaxel combined with fluorouracil) in the first-line treatment of advanced gastric cancer (AGC) Methods Fifty-five patients with AGC were treated with at least 3 cycles of FOLFOX-4 regimen (n = 26) or 2 cycles of DF regimen. Results The overall response rate (ORR) , disease control rate (DCR),median progression-free survival (mPFS) and median overall survival (mOS) were, respectively,26. 9%, 73. 1%,5. 68 months and 13. 89 months in FOLFOX-4 regimen treatment group ,and 20. 7% , 69. 0% ,3. 96 months and 12.71 months in DF regimen treatment group, with-out significant differences between the two groups (P>0. 05). The incidence of grade Ⅲ- Ⅳ neu-tropenia in DF regimen treatment group was significantly higher than that in FOLFOX-4 regimen treatment group(P<0. 05). Conclusion Both DF and FOLFOX-4 regimens are effective and tol-erable in the treatment of AGC.%目的 回顾性分析以奥沙利铂为基础的FOLFOX-4方案与以多西他赛为基础的DF方案一线治疗晚期胃癌的临床疗效和毒副反应.方法 收集中国人民解放军总医院55例晚期胃癌患者,一线应用FOLFOX-4方案26例,DF方案29例.所有患者至少接受3个周期FOLFOX-4方案或2个周期DF方案,且疗效可评价.结果 FOLFOX-4组客观有效率(ORR)为26.9%,疾病控制率(DCR)为73.1%,中位疾病无进展期(mPFS)为5.68月,中位总生存期(mOS)为13.89月.DF组ORR为20.7%,DCR为69.0%,mPFS为3.96月,mOS为12.71月.2组ORR、DCR、mPFS以及mOS比较差异均无统计学意义(均P>0.05).2组毒副反应出现Ⅲ-Ⅳ级白细胞减少DF组为多,2组比较差异有统计学意义(P<0.05).结论 FOLFOX-4和DF方案疗效相似,毒副作用可耐受,可以作为晚期胃癌的有效化疗方案选择.
展开▼
